Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Dezember 2025 07:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic...
12. Dezember 2025 16:05 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
08. Dezember 2025 08:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
20. November 2025 08:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT to Participate in 8th Annual Evercore Healthcare Conference

EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
17. November 2025 06:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Appoints Kristian Humer as Chief Financial Officer

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
14. November 2025 16:05 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
10. November 2025 08:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive...
06. November 2025 16:05 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Jefferies 2025 London Healthcare Conference

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
06. November 2025 06:23 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
06. November 2025 06:00 ET | Quelle: 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all...

Nächste Seite